AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis

/in

Tuesday October 25, 2016   SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections in patients suffering […]

Read more

REX Stroke and Brain Injury Clinical Trial in Australia

/in ,

Monday 24 October 2016. 24 October 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce the start of a new clinical trial treating patients who have had a stroke or brain injury, with Robot-Assisted Physiotherapy with REX.   The trial is being […]

Read more

BioScience to lure big super – The Australian

/in

Sarah-Jane Tasker – The Australian October 13, 2016 BioScience Managers is a small step away from running a $150 million fund under the government’s Biomedical Translation Fund, a move it says will revitalise the biotech sector. Jeremy Curnock-Cook, the managing director of Melbourne-based BioScience Managers, said the translation fund was an important initiative as it […]

Read more

BioScience Managers – New Bioscience Innovation Fund to Boost Australian Healthcare Startups

/in

Melbourne, Australia, 3 October, 2016 – Australia’s innovative healthcare and biomedical research sectors are set for a massive boost with the launch of a new venture capital fund. “This is a breakthrough moment for many earlier stage, unlisted companies,” said BioScience Managers’ managing director Jeremy Curnock Cook. “Access to funding is vital in turning ideas […]

Read more